Objectives: To describe sedation management in children supported on extracorporeal membrane oxygenation for acute respiratory failure. Design: Secondary analysis of prospectively collected data from a multicenter randomized trial of sedation (Randomized Evaluation of Sedation Titration for Respiratory Failure). Setting: Twenty-one U.S. PICUs.
S edation management is a ubiquitous and important aspect of pediatric critical care. The goals of sedation include maintenance of comfort, avoidance of agitation, and patient safety (1) . Therapeutic sedation risks hemodynamic and respiratory depression in the short term and tolerance, physical dependence, iatrogenic withdrawal syndrome (IWS), and potential for neurotoxicity in the long term (2, 3) . Recent focus has centered on identifying novel approaches that provide adequate sedation while minimizing these untoward effects (4) .
Sedation goals may be more difficult to achieve in pediatric patients undergoing extracorporeal membrane oxygenation (ECMO). Previous studies have shown that ECMO circuits alter the pharmacokinetics and pharmacodynamics of sedative medications (5) (6) (7) (8) (9) , although these effects with contemporary ECMO circuits are not well understood. These alterations are related to medication absorption by components of the ECMO circuit, where up to 40% of lorazepam and 50% of morphine doses can be extracted (10, 11) . In addition, ECMO-related physiologic and metabolic alterations raise concern for variations in sedative requirements in ECMO patients (12) . Escalating sedative requirements, as well as development of IWS, have been well described in the neonatal ECMO population (13, 14) .
Although ECMO circuit-related pharmacokinetic alterations in opioid and benzodiazepine concentrations are well known, little knowledge exists on the clinical effects of these issues outside the neonatal population, and an optimal approach to patient sedation on ECMO has not been achieved (15) . The purpose of this article is to describe sedation management in pediatric patients supported on ECMO for severe respiratory failure and to contrast sedation management using a nurseimplemented goal-directed sedation strategy to usual care.
MATERIALS AND METHODS
We performed a secondary analysis of prospectively collected data from the Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE) clinical trial. RESTORE was a multicenter cluster randomized trial that compared a nurseimplemented goal-directed sedation strategy to usual care in children 2 weeks to 17 years old with acute respiratory failure secondary to airways or parenchymal lung disease. The study protocol and findings have been described elsewhere (4) . Essential elements included daily team discussion of the patient's trajectory of illness (acute, titration, or weaning phase); prescribing a State Behavioral Scale (SBS) (16) target per phase of illness; arousal assessments if the patient was oversedated in the titration/weaning phases; daily extubation readiness testing; titrating sedatives at least every 8 hours; and either discontinuing or weaning sedatives per target Withdrawal Assessment Tool-Version 1 (17) based on length of exposure. This study was reviewed and approved by the institutional review board of each participating site.
Assessments of pain (18) (19) (20) , sedation (16) , and IWS (17) were standardized in all participating PICUs. Bedside care teams at intervention PICUs assigned a daily target sedation score per patient's phase of illness, and nurses used an algorithm to titrate sedatives to achieve the prescribed goal. Primary sedatives were morphine and midazolam. Per algorithm, patients supported on ECMO were considered to be in their acute phase of illness where the sedation goal is to maintain the status quo with an SBS of -1 (responsive to gentle touch or voice) or lower if deemed appropriate by the care team.
The RESTORE database includes demographic information, medical history data, baseline Pediatric Cerebral Performance Category and Pediatric Overall Performance Category (21) , Pediatric Risk of Mortality III-12 scores (22) , daily organ function scores, comfort assessments, and sedative dosing data from endotracheal intubation to study discharge (72 hr after the last opioid dose, day 28, or hospital discharge). Sedation profiles include total sedative exposure, use of neuromuscular blockade (NMB), sedation-related adverse events, and measures of wakefulness, pain, and agitation. ECMO data include mode of cannulation, equipment type, and center volume. Centers with greater than 10 ECMO cases in a calendar year were defined as high-volume centers for that year.
Statistical Analysis
Baseline patient characteristics were compared between ECMO patients and those not supported on ECMO. To facilitate appropriate comparisons, we excluded all data from sites not contributing at least one ECMO study patient and from all lower acuity patients unlikely to be supported on ECMO; specifically, patients with an oxygenation index less than 8.0 or oxygenation saturation index less than 7.5 (23) on the first 2 days after intubation.
For patients supported on ECMO, sedatives, sedation-related adverse events, and SBS scores are presented by day preceding, during, and subsequent to cannulation and decannulation (± 3 d), and sedative dose changes over time were evaluated. Clinical variables and outcomes surrounding cannulation and decannulation were considered separately to more clearly describe these clinically independent events during the course of ECMO. For cannulation, we included data from all ECMO patients. For decannulation, we only included data from ECMO patients successfully decannulated during the study period. In this subset of patients, we compared sedative dosing during ECMO and NMB use at decannulation by mode of ECMO support (venovenous vs veno-arterial), circuit configuration (polymethylpentene vs polypropylene oxygenator, roller vs centrifugal pump), age (< 2 vs ≥ 2 yr), and high-versus low-volume centers. We also compared sedative dosing during ECMO for patients who were comanaged with NMB for at least half of their ECMO course versus those who were not and those requiring renal replacement therapy (RRT) versus no RRT.
To assess the clinical impact of the RESTORE sedation protocol, sedative profiles were compared between ECMO patients in the usual care and intervention groups. We compared sedation requirements between ECMO and non-ECMO intervention group patients during their acute phase of illness.
In addition, the frequency of IWS was compared between the ECMO and non-ECMO groups, and between ECMO patients in the usual care and intervention groups.
All group comparisons were performed using linear, logistic, multinomial logistic, cumulative logit, and proportional hazards regression accounting for PICU as a cluster variable using generalized estimating equations for continuous, binary, nominal, ordinal, and time-to-event variables, respectively. Continuous variables except percentage of study days' variables were log-transformed. The statistical significance of sedative dose changes over time was evaluated using interceptonly linear regression. All data analyses were performed using SAS (Version 9.4, SAS Institute, Cary, NC).
RESULTS
Of 2,449 RESTORE patients from 31 PICUs, we excluded 482 patients from 10 PICUs that did not enroll an ECMO patient as well as 712 patients with at-risk/mild pediatric acute respiratory distress syndrome (PARDS) from the remaining 21 PICUs (nine usual care, 12 intervention). The 21 PICUs supported a median of 25 patients annually on ECMO (range, 2-77). Most centers (n = 18) supported more than 10 patients per year on ECMO during the course of the study. Sixty-one of the remaining 1,255 study patients (5%) were supported with ECMO, specifically veno-venous ECMO (n = 38, 62%) or veno-arterial ECMO (n = 23, 38%). ECMO equipment varied, with polymethylpentene oxygenators used for 34 patients (56%), polypropylene for 23 (38%), and silicone for four (7%). Centrifugal pumps were more commonly used (n = 35, 57%) than roller pumps. Table 1 describes the baseline characteristics of the 61 patients supported on ECMO compared to the 1,194 patients with moderate/severe PARDS not supported on ECMO. ECMO patients had more severe PARDS and exhibited more organ dysfunction on days 0-1. Over half of the 61 ECMO patients were cannulated by day 3 (median: interquartile range [IQR], 1-6) postintubation. Patients remained on ECMO support for a median of 9 study days prior to study discharge (IQR, (6) (7) (8) (9) (10) (11) (12) (13) (14) . Twenty-eight ECMO patients (46%) were successfully decannulated and extubated by the end of the study period, with a median length of intubation postdecannulation of 4 days (IQR, 3-8.5) . In addition, 13 (21%) were decannulated but remained intubated and 20 (33%) were not decannulated prior to study discharge. Of the 20 patients not decannulated, 10 died while on ECMO support, eight were still on ECMO on day 28, and two were still on ECMO upon transfer to a nonparticipating PICU. Table 2 shows daily sedation profiles around cannulation of all 61 ECMO patients. On the day of cannulation, median doses of opioid and benzodiazepines received were 0.15 mg/kg/hr (3.7 mg/kg/d) and 0.11 mg/kg/hr (2.8 mg/kg/d), respectively. With little change in sedative dosing in the 3 days prior to cannulation, significant increases in opioid and benzodiazepine doses were identified on each of the 3 days postcannulation (all p < 0.05). By the third day postcannulation, median daily opioid and benzodiazepine dose increased by 36% and 58%, respectively, from the day of cannulation for the 58 patients still on ECMO support. On this day, almost half of the patients were receiving NMB, approximately one third had modal SBS scores of -3/-2, and the remaining were more awake. Table 3 shows daily sedation profiles around decannulation of the 41 ECMO patients successfully decannulated by the end of the study period. On the day of decannulation, patients were receiving 0.40 mg/kg/hr opioids (9.7 mg/kg/d) and 0.39 mg/kg/hr benzodiazepines (9.4 mg/kg/d). Opioid and benzodiazepine doses increased significantly from cannulation to decannulation day (p < 0.001 for each). Median daily opioid and benzodiazepine doses increased 108% and 192%, respectively, over this time period for the 41 patients successfully decannulated prior to study discharge. Contrary to the time after cannulation, opioid and benzodiazepine doses significantly decreased for the 3 days postdecannulation (all p < 0.05). For the 40 patients still on study, by the third day postdecannulation, median daily opioid and benzodiazepine doses decreased by 35% and 24%, respectively, and modal SBS scores shifted to an awake state.
Restricting to the 41 patients successfully decannulated prior to study discharge, there were no differences in sedation dosing during ECMO or the percentage of patients receiving NMB on the day of decannulation by ECMO mode, center volume, or age group. Those supported on polymethylpentene versus polypropylene oxygenators and/or roller versus centrifugal pumps received higher mean daily benzodiazepine doses during ECMO (median, 0.33 vs 0.19 mg/kg/hr, p < 0.001; 0.34 vs 0.21 mg/kg/hr, p = 0.001, respectively), but similar opioid doses and NMB use at decannulation. There were no differences in sedation dosing during ECMO between patients comanaged with NMB and those who were not. RRT patients (n = 16) had more study days on ECMO (median, 11.5 vs 6 d; p < 0.001) and were exposed to more opioids compared with non-RRT patients: median mean daily dose 0.38 versus 0.24 mg/kg/hr (p = 0.050) and median cumulative dose 88.6 versus 36.6 mg/kg (p = 0.004).
We compared sedation profiles of ECMO patients by RESTORE treatment group (32 usual care, 29 intervention). There were no treatment group differences in either opioid or benzodiazepine daily doses during 3 days precannulation through 3 days postcannulation (Fig. 1) . Restricting to the 41 patients successfully decannulated prior to study discharge (23 usual care, 18 intervention), usual care patients received more opioids during the entire study period compared with intervention patients: median mean daily dose 0.26 versus 0.15 mg/kg/ hr (p = 0.03), median cumulative dose 183.0 versus 89.8 mg/kg (p = 0.02), and median length of exposure 29 versus 22.5 days (p = 0.002). Usual care and intervention group patients received similar mean daily doses of benzodiazepines (median, 0.23 vs 0.16 mg/kg/hr; p = 0.72). Patients in both groups spent similar amounts of time awake and calm (median, 70% vs 66% intubated days; p = 0.86) and days to first awake and calm state (9 vs 4 d; p = 0.20) . Modal pain scores were rarely greater than 4 in either group. Patients in the usual care arm experienced fewer study days with any episode of pain (30% vs 50%; p = 0.004); percentage of days with any episode of agitation was not significantly different between groups. Two days postdecannulation, the usual care group received more opioids (0.32 vs 0.26 mg/kg/hr; p = 0.03) and more sedative classes (3 vs 2; p = 0.02) than the intervention group. During RESTORE's acute phase of illness, intervention group patients supported on ECMO (n = 29) received higher mean daily doses of both opioids (median, 0.23 vs 0.10 mg/kg/hr; p < 0.001) and benzodiazepines (0.28 vs 0.09 mg/kg/hr; p < 0.001) (13) 292 (24) Acute respiratory failure related to sepsis 14 (23) 197 (17) Asthma or reactive airway disease 6 (10) 87 (7) Aspiration pneumonia 1 (2) 71 (6) Other b 4 (7) 136 (11) Past medical history, n (%) Prematurity (< 36 wk postmenstrual age) 8 (13) 188 (16) Neuromuscular blockade for the entire duration of days 0-2, n (%) 15 (25) 115 (10) 0.009 ECMO = extracorporeal membrane oxygenation, IQR = interquartile range, OI = oxygenation index, OSI = oxygen saturation index, PRISM III-12 = Pediatric Risk of Mortality III score from first 12 hours in the PICU. a p values for the comparison between groups were calculated using linear, logistic, multinomial logistic, and cumulative logit regression for log-transformed continuous, binary, nominal, and ordinal variables, respectively. All regression analyses except for primary diagnosis accounted for PICU as a cluster variable using generalized estimating equations. b Other primary diagnoses include pulmonary edema, thoracic trauma, pulmonary hemorrhage, laryngotracheobronchitis, acute respiratory failure after bone marrow transplantation, acute chest syndrome/sickle cell disease, pertussis, pneumothorax (nontrauma), acute exacerbation lung disease (cystic fibrosis or bronchopulmonary dysplasia), acute respiratory failure related to multiple blood transfusions, pulmonary hypertension (not primary), and pulmonary embolus. c Oxygenation index was calculated as ([Fio 2 × mean airway pressure]/Pao 2 × 100). When an arterial blood gas measurement was not available, Spo 2 was used to estimate Pao 2 in order to calculate OSI ([Fio 2 × mean airway pressure]/Spo 2 × 100). Lower scores reflect better oxygenation. d Number of organ dysfunctions ranges from 1 to 6. All patients had respiratory dysfunction. Cardiovascular dysfunction based on vasoactive medication use (single or multiple). Neurologic dysfunction based on worst level of consciousness (stupor or coma) or pupillary response (one or both pupils nonreactive). Hematologic dysfunction based on platelet threshold (< 80 K/µL). Renal dysfunction based on age-specific creatinine thresholds. Hepatic dysfunction based on age-and gender-specific alanine transaminase thresholds or total bilirubin thresholds.
Critical Care Medicine No. of benzodiazepine bolus doses, median (IQR)
Secondary sedatives, n (%) Dexmedetomidine 6 (19) 7 (20) 8 (15) 8 (13) 11 (18) 13 (21) 10 (17) Propofol 0 0 0
Barbiturates 2 (6) 1 (3) 3 (6) 4 (7) 5 (8) 8 (13) 7 (12) Ketamine 3 (10) 2 (6) 6 (12) 10 (16) 3 (5) 5 (8) 6 (10) Clonidine 2 (6) 3 (9) 3 (6) 4 (7) 3 (5) 3 (5) 4 (7) Chloral hydrate 0 0 0 0 1 (2) 1 (2) 1 (2) No. of different sedative classes received, median
Inadequate sedation management, n (%)
Sedation scores e n = 27 n = 35 n = 47 n = 59 n = 56 n = 58 n = 56
Modal SBS score, n (%)
-1/0 6 (22) 5 (14) 4 (9) 4 (7) 6 (11) 6 (10) 9 (16) -3/-2 7 (26) 12 (34) 9 (19) 15 (25) 20 (36) 23 (40) 19 (34) NMB entire day 14 (52) 18 (51) 33 (70) 40 (68) 30 (54) 27 (47) 26 (46) Highest SBS score, n (%) +1/+2 3 (11) 3 (9) 4 (9) 4 (7) 7 (13) 7 (12) 10 (18) -1/0 8 (30) 7 (20) 2 (4) 3 (5) 9 (16) 13 (22) 10 (18) -3/-2 2 (7) 7 (20) 8 (17) 12 (20) 10 (18) 11 (19) 10 (18) NMB entire day 14 (52) 18 (51) 33 (70) 40 (68) 30 (54) 27 (47) 26 ( 8.7 (4.8-12.6) 7.5 (4.8-13.3) 6.5 (3.6-12.5) No. of benzodiazepine bolus doses, median (IQR)
Secondary sedatives, n (%) Dexmedetomidine 10 (26) 12 (29) 11 (27) 11 (27) 14 (34) 13 (32) 14 (35) Propofol 0 1 (2) 2 (5) 2 (5) 0 0 1 (3) Barbiturates 7 (18) 10 (24) 12 (29) 13 (32) 12 (29) 9 (22) 8 (20) Ketamine 5 (13) 4 (10) 5 (12) 7 (17) 5 (12) 2 (5) 3 (8) Clonidine 3 (8) 4 (10) 4 (10) 4 (10) 4 (10) 5 (12) 5 (13) Methadone 1 (3) 1 (2) 1 (2) 1 (2) 6 (15) 10 (24) 15 (38) Chloral hydrate 1 (3) 1 (2) 1 (2) 1 (2) 3 (7) 3 (7) 2 (5) No. of different sedative classes received, median (IQR)
Sedation-related adverse events e Inadequate pain management, n (%)
Clinically significant iatrogenic withdrawal, n (%)
Sedation scores f n = 38 n = 39 n = 38 n = 40 n = 40 n = 37 n = 39
Modal SBS score, n (%) +1/+2 0 0 0 0 3 (8) 1 (3) 3 (8) -1/0 8 (21) 13 (33) 10 (26) 12 (30) 22 (55) 27 (73) 24 (62) -3/-2 11 (29) 6 (15) 8 (21) 9 (23) 6 (15) 3 (8) 3 (8) NMB entire day 19 (50) 20 (51) 20 (53) 19 (48) 9 (23) 6 (16) 3 (8) No longer intubated 0 0 0 0 0 0 6 (15) Lowest SBS score, n (%) (15) 5 (13) 8 (20) 14 (35) 22 (59) 23 (59) -3/-2 16 (42) 13 (33) 13 (34) 13 (33) 16 (40) 9 (24) 7 (18) NMB entire day 19 (50) 20 (51) 20 (53) 19 (48) 9 (23) 6 (16) and received more classes of sedatives (3 vs 2; p < 0.001) than intervention group patients not on ECMO (n = 462). Further, during the acute phase, intervention ECMO patients more commonly received NMB for at least 1 entire day than intervention non-ECMO patients (83% vs 45%; p < 0.001). Clinically significant iatrogenic withdrawal occurred more frequently in ECMO than in non-ECMO patients (27% vs 10%; p < 0.001) ( Table 4) , and no age-based differences in clinically significant IWS were noted. No differences were found in median PICU (27.9 vs 28.8 d; p = 0.62) 
DISCUSSION
Here, we describe sedation management in children supported on ECMO for acute respiratory failure. Our data demonstrate the unique, dynamic, and challenging clinical paradigm presented by pediatric patients with moderate or severe PARDS supported on ECMO. We quantify the trajectory of ECMO sedation management and report a significant increase in opioid and benzodiazepine dosing postcannulation, continued dose escalation throughout the duration of ECMO support, and development of IWS postdecannulation. Although 30% of ECMO patients are awake and calm on the day of decannulation, the vast majority of ECMO patients remained deeply sedated and/or received NMB throughout their ECMO run. Postdecannulation, nearly 90% of ECMO patients exhibited symptoms of iatrogenic withdrawal and over a quarter required rescue treatment of IWS. Our data also show that a nurse-managed sedation protocol may help limit total sedative exposure in these patients.
In young children, the large ECMO cannulas and their precise positioning require a calm patient. Although this may require the use of large doses of sedatives, the mechanism for increased sedative requirements during ECMO is likely multifactorial. Although extraction of medications by the ECMO circuit is well described (8, (10) (11) (12) , additional factors including expanded volume of distribution and blood administration can alter medication clearance and bioavailability. Patientspecific alterations in organ function resulting from increased perfusion may affect pharmacokinetics and pharmacodynamics of sedatives. The use of RRT during ECMO may also contribute to increased medication requirements.
Our findings support previous data, including the need for a rapid increase in sedative dosing following ECMO cannulation to achieve sedation targets (12, 24) . In the first 3 days postcannulation, most ECMO patients in our study received NMB and/or were heavily sedated. We found that opioid and benzodiazepine doses increased by 36% and 58%, respectively. By the time of decannulation, ECMO patients were receiving more than double their pre-ECMO doses of these medications for a lighter level of sedation.
Recent data on ECMO management have challenged the use of deep sedation and NMB and emphasize need for early rehabilitation especially in those bridging to lung transplantation on ECMO (25) . However, we demonstrate that deep sedation and NMB remain common in patients with acute hypoxemic respiratory failure receiving ECMO. This finding was unrelated to center ECMO volume, suggesting that it may be related to severity of illness of the patients in our cohort.
We demonstrate the effect of discontinuing ECMO on sedation requirements and levels of sedation. Discontinuation of the ECMO circuit and NMB, and reduced sedation levels' goals Highest SBS score, n (%) +1/+2
6 (16) 9 (23) 7 (18) 10 (25) 14 (35) 20 (54) 22 (56) -1/0 9 (24) 9 (23) 10 (26) 8 (20) 15 (38) 11 (30) 7 (18) -3/-2 4 (11) 1 (3) 1 (3) 3 (8) 2 ( (50) 20 (51) 20 (53) 19 (48) 9 (23) 6 (16) 3 (8) No longer Excluded 20 patients who were not decannulated prior to study discharge (10 patients died on extracorporeal membrane oxygenation (ECMO) support, eight patients still on ECMO on day 28, and two patients still on ECMO on day of transfer to nonparticipating PICU). postdecannulation decreased sedative use (5, 6, 8, 9) . Within 3 days of decannulation, patients had shifted to a more awake state, and by the fourth day, half of the patients were successfully extubated. The diagnosis of physiologic tolerance, defined as a decreasing clinical effect of a sedative after prolonged exposure, is difficult to operationalize in patients supported on ECMO (26) . However, the continued escalation of doses following cannulation and the prevalence of IWS postdecannulation suggests that tolerance occurs more frequently than previously appreciated (13, 14) . Specifically, the ECMO circuit is not protecting the patient from increased sedative exposure during ECMO support, a situation that places them at high risk for IWS postdecannulation. In our cohort, patients on ECMO experienced IWS more frequently than comparable patients not supported on ECMO. Both increased exposure to sedatives and the resulting increase in withdrawal are of concern, as data suggest Critical Care Medicine www.ccmjournal.org e1009 exposure to sedatives and IWS impairs long-term neurodevelopmental outcomes (3, 27) .
When comparing patients supported on ECMO in the RESTORE intervention group to those in the usual care group, patients in the intervention group were exposed to less opioids during the study period, despite similar sedative exposure prior to cannulation. Further, intervention patients experienced 6.5 fewer total sedative exposure days. These data suggest that the exposure to opioids and benzodiazepines on ECMO can be mitigated with the use of a standardized, goal-directed, nursedriven sedation protocol. This must be weighed against the finding that the usual care ECMO patients experienced fewer days with episodic pain compared with intervention patients.
There are several limitations to this study. First, unmeasured variables may have influenced clinical decision-making. Second, as a subset of a larger study, this analysis was not sufficiently powered to answer all questions of interest. Third, we attempted to compare ECMO patients to patients not requiring ECMO who had similar severity of lung disease. Although both groups consisted of patients with moderate or severe PARDS, there may have been unmeasured physiologic or metabolic alterations in patients that contributed to the differences identified. Fourth, we were unable to characterize the full ECMO course for 10 patients who were still on ECMO support at the end of the study period. Nonetheless, the rapid increase in sedative dosing following cannulation and decrease in the days following decannulation suggest that interaction between the ECMO circuit and drug pharmacokinetics plays a clinically significant role in patients supported by ECMO.
Despite these limitations, our findings build on existing research (9, 12, 24) and provide granular data that explore the dynamic patient-ECMO-sedation interactions experienced during ECMO. Further, we demonstrate a clear association with the use of ECMO and the development of IWS. Lastly, our data demonstrate the potential benefit of a nurse-managed protocolized approach to sedation for ECMO patients which deserves future prospective investigation.
CONCLUSIONS
The provision of ECMO in children is associated with deep sedation, substantial sedative exposure, and an increased frequency of IWS. It is incumbent upon the pediatric ECMO community to evaluate sedation practices that may be potentially harmful. Standardized, goal-directed, nurse-driven sedation protocols may help mitigate these effects.
